Kenya in the 2000s
This chapter looks at the conditions that led pharmaceutical manufacturers in Kenya to invest in the production of a broader range of drugs, and to improve quality standards beyond what was required by local regulations. It begins with the contentious negotiations over Trade-Related Aspects of Intellectual Property Rights (TRIPS), which resulted in donors providing to some developing countries not only markets, as they did in the 1980s, but also monitoring and mentoring. In Kenya, a new market of interest to local manufacturers, for anti-AIDS and antimalarial drugs, was created when the Global Fund to Fight AIDS, Tuberculosis and Malaria—among other donors—did not a priori exclude local manufacturers from tenders. To participate in these tenders, however, drugs manufacturers had to receive WHO prequalification (PQ) confirming that their drugs were produced following international, rather than only local, quality standards. This monitoring gave local producers an incentive to improve their manufacturing practices. In turn, development agencies offered training and other forms of mentoring—giving local producers the means to learn how to produce drugs following these higher quality standards.